We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Molecular Biology Test Detects Human Papillomavirus

By HospiMedica staff writers
Posted on 30 Apr 2007
A molecular diagnostic test enables the detection of human papillomavirus (HPV) in cervical cancer surveillance.

Cervical cancer is caused in 99.7% of cases by persistent infection with HPV. More...
Most HPV infections are transient and do not induce cervical cancer. However, a small but significant number of HPV infections progress to cervical cancer. It is the expression of viral oncoproteins E6 and E7, which initiate the cervical cancer process, that makes them early cancer markers. It has also been demonstrated that genotypes 16 and 18 cause approximately 70% of cervical cancers worldwide.

Most cervical cancer surveillance methods currently in use detect viral DNA. Such testing, however, does not make it possible to most effectively assess the virus' oncogenicity. Developed by bioMérieux (Marcy l'Etoile, France), NucliSens EasyQ HPV is based on a new concept that benefits from all the latest discoveries in the field, directly determining the expression of oncogenic risk factors by detecting the mRNA of the E6 and E7 proteins.

NucliSENS HPV EasyQ is the first real-time amplification/detection test with this degree of automation to be CE-marked. It is currently available in France, the Netherlands, Belgium, Switzerland, Spain, and Austria and will be progressively marketed in other countries according to local regulations.

The test enhances the quality of women's lives by reducing the need for invasive examinations and treatments. "This new molecular diagnostic test reinforces bioMérieux's offer in the field of oncology. The test contributes to the fight against cancer and complements current methods for the detection and monitoring of cervical cancer. This new product strongly reinforces the value of our molecular biology platform, NucliSENS EasyQ, for our customers and future prospects,” said Stéphane Bancel, CEO of bioMérieux.

bioMérieux provides diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination to improve patient health and ensure consumer safety. The products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring.


Related Links:
bioMérieux

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.